ABTI — Alterola Biotech Cashflow Statement
0.000.00%
Last trade - 00:00- $5.01m
- $5.25m
Annual cashflow statement for Alterola Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2019 September 30th | 2020 September 30th | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 6 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-KT | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.259 | -0.251 | -0.309 | -6.47 | -1.74 |
| Deferred Taxes | |||||
| Non-Cash Items | 0.126 | 0.13 | 0.243 | 5.76 | 0.927 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.133 | 0.121 | 0.017 | 0.756 | -0.035 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0 | 0 | -0.05 | 0.044 | -1.04 |
| Capital Expenditures | 0 | 0 | 0 | 0 | — |
| Purchase / Acquisition of Intangibles | |||||
| Software Development Costs | |||||
| Other Investing Cash Flow Items | — | — | — | — | -0.14 |
| Purchase of Investments | |||||
| Cash from Investing Activities | 0 | 0 | 0 | 0 | -0.14 |
| Financing Cash Flow Items | — | — | 0.05 | -0.543 | -0.003 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0 | 0 | 0.05 | -0.01 | 1.21 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0 | 0 | 0 | 0.063 | -0.055 |